Takeda doubles down on Finch's microbiome insights, signing up for a second project in Crohn's disease
Takeda first shone a spotlight on Finch Therapeutics’ human-first discovery platform in 2017, when the Japanese pharma paid $10 million to partner a preclinical ulcerative colitis program inspired by fecal transplantation. While the microbiome therapy, FIN-524, is still making its way to the clinic, Takeda has seen enough to commit to a second program tackling another type of inflammatory bowel disease.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
